---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105306"
form_type: "8-K"
ticker: "CYDY"
cik: "0001175680"
company_name: "CytoDyn Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:50:06.442496+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CytoDyn secures $30M equity funding commitment from Yorkville Advisors over 36 months

## Summary
- Up to $30M in common stock sales to Yorkville over 36 months; company controls timing, no minimum draws.
- Shares priced at 98% of lowest 3-day VWAP; Yorkville capped at 4.99% beneficial ownership.
- Commitment fee of 1% paid in shares (half immediately, half at 6 months); structuring fee $25k.
- Proceeds for working capital, debt repayment, and leronlimab PD-L1 program development.
- No warrants or derivatives; registration statement to be filed for resale.

## SEC filing metadata
- accession: 0001104659-25-105306
- form_type: 8-K
- ticker: CYDY
- cik: 0001175680
- company_name: CytoDyn Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175680/000110465925105306/0001104659-25-105306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175680/000110465925105306/cydy-20251103x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105306
- JSON: https://secwatch.observer/filing/0001104659-25-105306.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.